ARCT
Arcturus Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARCT
Arcturus Therapeutics Holdings Inc.
A company that developing lipid nanoparticle siRNA drug delivery systems for the orphan disease market
10628 Science Center Drive, Suite 250, San Diego, California 92121
--
Arcturus Therapeutics Holdings Inc., registered in Israel, began operations on February 7, 2008. The company is a global messenger RNA drug company focused on developing infectious disease vaccines and therapies for rare liver and respiratory diseases. The company is leveraging its proprietary LUNAR platform and nucleic acid technology to develop and advance a range of mRNA-based vaccines and therapies for infectious diseases and rare genetic diseases with significant unmet medical needs.
Earnings Call
Q1/2025
Estimate EPS-1.1
Actual EPS-0.52
Estimate Revenue23.35M
Actual Revenue29.38M
Arcturus Q1 2025: Contradictions Unveiled in CF Study Design, Safety, and Cash Strategy
May 20,2025 06:35
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.8
Actual EPS-0.49
Estimate Revenue16.03M
Actual Revenue17.15M
Arcturus Therapeutics Q3 2025: Contradictions Emerge on Study Dose Levels, CF Enrollment Pacing, and Regulatory Strategy for KOSTAIVE
Nov 10,2025 09:25
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ARCT has released its 2025 Q3 earnings. EPS was reported at -0.49, versus the expected -0.8, beating expectations. The chart below visualizes how ARCT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ARCT has released its 2025 Q3 earnings report, with revenue of 17.15M, reflecting a YoY change of -58.84%, and net profit of -13.45M, showing a YoY change of -94.81%. The Sankey diagram below clearly presents ARCT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
